N-acetylcysteine for antioxidant therapy : pharmacology and clinical utility Dodd, Seetal, Dean, Olivia, Copolov, David L., Malhi, Gin S. and Berk, Michael 2008, N-acetylcysteine for antioxidant therapy : pharmacology and clinical utility, Expert opinion on biological therapy, vol. 8, no. 12, pp. 1955-1962, doi: 10.1517/14728220802517901. Attached Files Name Description MIMEType Size Downloads Title N-acetylcysteine for antioxidant therapy : pharmacology and clinical utility Formatted title N-acetylcysteine for antioxidant therapy : pharmacology and clinical utility Author(s) Dodd, Seetal orcid.org/0000-0002-7918-4636 Dean, Olivia orcid.org/0000-0002-2776-3935 Copolov, David L. Malhi, Gin S. Berk, Michael orcid.org/0000-0002-5554-6946 Journal name Expert opinion on biological therapy Volume number 8 Issue number 12 Start page 1955 End page 1962 Total pages 8 Publisher Informa Healthcare Place of publication London, England Publication date 2008-12-01 ISSN 1354-3776 1744-7674 Keyword(s) antioxidant glutathione mucolytic N -acetylcysteine oxidative stress Summary Glutathione is an endogenous antioxidant and has a ubiquitous role in many of the body’s defences. Treatment with N -acetylcysteine (NAC) has been shown to increase levels of glutathione. NAC has been proposed as a treatment for several illnesses. Objectives : The efficacy and tolerability of NAC was examined across a range of conditions to evaluate the evidence supporting the use of NAC for each indication. Methods : A literature search was conducted using PubMed. Information was also collected from other online sources including the websites of the Therapeutic Goods Administration of Australia and the FDA. Results : Reports ranged from case studies to clinical trials. There is strong evidence to support the use of NAC for the treatment of paracetamol overdose and emerging evidence suggesting it has utility in psychiatric disorders, particularly schizophrenia and bipolar disorder. NAC is safe and well tolerated when administered orally but has documented risks with intravenous administration. Language eng DOI 10.1517/14728220802517901 Field of Research 119999 Medical and Health Sciences not elsewhere classified Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences HERDC Research category C1.1 Refereed article in a scholarly journal Copyright notice ©2008, Informa UK Persistent URL http://hdl.handle.net/10536/DRO/DU:30035480 Document type: Journal Article Collections: Faculty of Health School of Medicine Related Links Link Description Connect to published version (restricted access) Go to link with your DU access privileges     Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved. Versions Version Filter Type Tue, 21 Jun 2011, 14:40:14 EST Tue, 04 Oct 2011, 11:00:58 EST Tue, 04 Oct 2011, 11:07:48 EST Tue, 04 Oct 2011, 11:12:13 EST Tue, 04 Oct 2011, 11:17:22 EST Tue, 04 Oct 2011, 15:00:48 EST Tue, 04 Oct 2011, 15:02:03 EST Mon, 16 Jun 2014, 18:20:56 EST Thu, 11 Dec 2014, 17:09:57 EST Filtered Full Citation counts:   Cited 261 times in TR Web of Science Cited 284 times in Scopus Search Google Scholar Access Statistics: 932 Abstract Views, 4 File Downloads  -  Detailed Statistics Created: Tue, 21 Jun 2011, 14:40:14 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.